Leading Proxy Advisory Firms Recommend Vote in Favor of All Proposals for Teva Pharmaceutical's Annual Meeting

  Leading Proxy Advisory Firms Recommend Vote in Favor of All Proposals for
  Teva Pharmaceutical's Annual Meeting

                    Shareholders Reminded to Vote Promptly

Business Wire

JERUSALEM -- August 14, 2013

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that ISS
Proxy Advisory Services (“ISS”) and Glass Lewis, the leading international
proxy advisory services, have recommended that shareholders vote for
re-election of all director nominees and in favor of all proposals at the
upcoming annual meeting of shareholders to be held on Tuesday, August 27,
2013. Holders of the Company’s American Depositary Shares are reminded that in
order to have their shares voted, their instructions must be received no later
than August 23, 2013, at 12:00 noon, Eastern Daylight Time.

Our Board of Directors unanimously recommends that shareholders vote for
re-election of all director nominees and in favor of all other proposals. (See
below regarding questions about a shareholder’s personal interest in certain
matters.)

ISS, the largest proxy advisory service, provides voting analysis on more than
20,000 shareholder meetings per year to mutual funds, financial institutions
and hedge funds. In its analysis regarding proposal 2b (approval of 2013 bonus
objectives and payout terms for the CEO), ISS stated that the “proposed bonus
policy appears to be reasonably structured” and regarding proposal 3 (approval
of compensation policy), that the “proposed policy appears to be in line with
local market practice, and ISS is not aware of any circumstances that would
call its suitability into question.”

Glass Lewis, another highly respected proxy advisory service, stated, in its
analysis of Teva’s compensation policy, “Overall, the Company has provided
adequate disclosure regarding its executive compensation program. We have not
identified any significant issues for shareholder concern and believe that the
Company has designed appropriate incentive plans that will link pay for
performance going forward.”

Under Israeli law, shareholders must indicate whether or not they have a
“personal interest” in the proposal in order for their votes to be counted on
proposals 2a and 2b (approval of the 2012 cash bonus and 2013 bonus objectives
and payout terms for the CEO) and 3 (approval of the Company’s compensation
policy). A shareholder would have a personal interest if, for example, he (or
his spouse, relative or any of the other persons or entities described in
pages 1-2 of the Company’s proxy statement, collectively, a “related party”)
is the subject of the proposal, is covered by the policy or otherwise stands
to personally gain from the proposal. An interest in the proposal arising
solely as a shareholder is not considered a personal interest under Israeli
law.

For example, if a shareholder is the CEO (or a related party of the CEO), the
shareholder would have a personal interest in proposals 2a and 2b, regarding
the CEO’s bonuses. Likewise, if the shareholder is a director or executive
officer (or a related party of a director or executive officer), the
shareholder would have a personal interest in proposal 3, regarding the
Company’s compensation policy. Since the vast majority of the Company’s
shareholders are not executive officers, directors or other office holders or
related parties of such persons, the Company expects that the vast majority of
shareholders do not have a personal interest in proposals 2(a), 2(b) and 3 and
accordingly would vote NO where asked whether they have a personal interest in
such proposal.

The Company encourages all shareholders to vote their shares promptly by
phone, Internet, or by mailing their voting instruction card. Shareholders who
need assistance or have questions should call the Company’s proxy solicitor,
MacKenzie Partners, Inc., toll-free at (800) 322-2885 or collect at (212)
929-5500. Voting instruction cards and the proxy statement can also be
obtained by contacting MacKenzie.

About Teva

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical
company, committed to increasing access to high-quality healthcare by
developing, producing and marketing affordable generic drugs as well as
innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a
direct presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.

Contact:

Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin C. Mannix, 215-591-8912
or
Ran Meir, 215-591-3033
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR:
Israel
Iris Beck Codner, 972 (3) 926-7687
or
United States
Denise Bradley, 215-591-8974
 
Press spacebar to pause and continue. Press esc to stop.